Drug-Drug Interaction Study of Atumelnant in Healthy Participants
← catalyst calendarSponsored by Crinetics Pharmaceuticals Inc. (industry) · CRNX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
46actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-28 | actual | When the study began enrolling |
| Primary completion | 2026-06-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-30 | actual | The whole study's end, after follow-up |
| First posted | 2026-05-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: Atumelnant — also filed as CRN04894
- Drug: Carbamazepine
- Drug: Midazolam
- Drug: Digoxin
- Drug: Metformin
Primary outcomes
what the primary-completion date above is the date OFCohort 1: Pharmacokinetics (AUC 0-last)
measured Up to Day 34
Cohort 1: Pharmacokinetics (AUC 0-inf)
measured Up to Day 34
Cohort 1: Pharmacokinetics (Cmax)
measured Up to Day 34
Cohort 2: Pharmacokinetics (AUC 0-last)
measured Up to Day 21
Cohort 2: Pharmacokinetics (AUC 0-inf)
measured Up to Day 21
Cohort 2: Pharmacokinetics (Cmax)
measured Up to Day 21
Permalink · CRNX's whole pipeline · Catalyst calendar · Every registered study · What changed